However, there are also successful cases, such as the up-regulation of FASN expression in lung cancer, which is associated with poor prognosis, and inhibitors targeting FASN, such as orlistat, can inhibit tumor growth by preventing EGFR palmitoylation and enhancing its ubiquitination 223. Here, FASN is linked to lung carcinoma.